ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022
Infectivity versus fatality of SARS-CoV-2 mutations and influenza.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Modeling the effects of meteorological factors and media-driven public awareness on seasonal influenza outbreaks.PloS one · 2026Article
- Hidden burden of pneumococcal colonization in adults with viral respiratory infections: the role of influenza and RSV.Frontiers in cellular and infection microbiology · 2026Article
- Infectivity and fatality of influenza in pre- and post-COVID-19 pandemic year.PLoS computational biology · 2025Article
- Prediction of SARS-CoV-2 infection cases based on the meta-SEIRS model.Epidemiology and infection · 2024Article
- The spatial-temporal variations and influencing factors of COVID-19 case fatality rate: a worldwide study in 30 countries from February 2021 to May 2022.Epidemiology and infection · 2024Article
- Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study.BMC infectious diseases · 2024Article
- The Clinical Severity of COVID-19 Variants of Concern: Retrospective Population-Based Analysis.JMIR public health and surveillance · 2024Article
- Risk Index of Regional Infection Expansion of COVID-19: Moving Direction Entropy Study Using Mobility Data and Its Application to Tokyo.JMIR public health and surveillance · 2024Article
- Clinical and Genomic Perspective of SARS CoV-2 Infection in Liver Disease Patients: A Single-Centre Retrospective Study.Current microbiology · 2024Article
- Public acceptance of COVID-19 control measures and associated factors during Omicron-dominant period in China: a cross-sectional survey.BMC public health · 2024Article
- Prevention and control of infectious disease transmission in subways: an improved susceptible-exposed-infected-recovered model.Frontiers in public health · 2024Article
- Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study.PLoS medicine · 2023Article
- A comprehensive Drosophila resource to identify key functional interactions between SARS-CoV-2 factors and host proteins.Cell reports · 2023Article
- AnPathogens (Basel, Switzerland) · 2023Article
- Vaccine hesitancy promotes emergence of new SARS-CoV-2 variants.Journal of theoretical biology · 2023Article
- Article
- Simultaneous Quantitative SARS-CoV-2 Antigen and Host Antibody Detection and Pre-Screening Strategy at the Point of Care.Bioengineering (Basel, Switzerland) · 2023Article
- Genesis, evolution and effectiveness of Singapore's national sorting logic and home recovery policies in handling the COVID-19 Delta and Omicron waves.The Lancet regional health. Western Pacific · 2023Review
- Health Care Implications of the COVID-19 Pandemic for the Cardiovascular Practitioner.The Canadian journal of cardiology · 2023Review
- Social implications of a change in the legal classification of COVID-19: The need for pandemic prevention, preparedness, and healthcare system strengthening.Global health & medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBecause of the spread of the Omicron variant, many countries have experienced COVID-19 case numbers unseen since the start of the pandemic. We aimed to compare the epidemiological characteristics of Omicron with previous variants and different strains of influenza to provide context for public health responses.
methodsWe developed transmission models for SARS-CoV-2 variants and influenza, in which transmission, death, and vaccination rates were taken to be time-varying. We fit our model based on publicly available data in South Africa, the United States, and Canada. We used this model to evaluate the relative transmissibility and mortality of Omicron compared with previous variants and influenza.
resultsWe found that Omicron is more transmissible and less fatal than both seasonal and 2009 H1N1 influenza and the Delta variant; these characteristics make Omicron epidemiologically more similar to influenza than it is to Delta. We estimate that as of February 7, 2022, booster doses have prevented 4.29×10
conclusionOur findings indicate that the high infectivity of Omicron will keep COVID-19 endemic, similar to influenza. However, because of Omicron's lower fatality rate, our work suggests that human populations living with SARS-CoV-2 are most likely.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.